title: [Pharmacological and clinical profile of a novel DPP-4 inhibitor teneligliptin hydrobromide hydrate (TENELIA(®)].
authors.affiliation: gouda.maki@mm.mt-pharma.co.jp
authors.forename: Maki
authors.initials: M
authors.lastname: Goda
authors.forename: Fumihiko
authors.initials: F
authors.lastname: Akahoshi
authors.forename: Shinichi
authors.initials: S
authors.lastname: Ishii
authors.forename: Ryuji
authors.initials: R
authors.lastname: Terata
authors.forename: Yoshiharu
authors.initials: Y
authors.lastname: Hayashi
mesh_terms: D000328:Adult; D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use*; D006801:Humans; D011720:Pyrazoles / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D051381:Rats; D011924:Rats, Zucker; D053778:Thiazolidines / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*
chemical_list: C579035:3-(4-(4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl)pyrrolidin-2-ylcarbonyl)thiazolidine; D001786:Blood Glucose; D054873:Dipeptidyl-Peptidase IV Inhibitors; D011720:Pyrazoles; D053778:Thiazolidines